Literature DB >> 1283753

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.

S Magrin1, A Craxì, C Fabiano, G Fiorentino, L Marino, P Almasio, G B Pinzello, U Palazzo, M Vitale, A Maggio.   

Abstract

Hepatitis C virus (HCV) replication was assessed before and during alpha-interferon (IFN) treatment in 22 anti-HCV positive patients with posttransfusion or sporadic chronic hepatitis (CH). Eleven patients were "responders" and 11 patients "non-responders" to IFN. Thirteen anti-HCV negative healthy subjects and five anti-HCV negative patients with autoimmune CH served as controls. Serum HCV-RNA was detected by the polymerase chain reaction (PCR) in all untreated anti-HCV positive patients but in none of the anti-HCV negative subjects. PCR primers from the 5'-noncoding (NC) region were more sensitive than primers from a non-structural (NS5) region in detecting HCV-RNA (21/22, 95% vs. 7/22, 32%, respectively). Positive strand HCV-RNA titre and positivity rate for the negative strand were similar in responders and non-responders before IFN treatment, as well as anti-c100-3 titre by enzyme-linked immunosorbent assay (ELISA), and anti-5-1-1, anti-c33c, anti-c22 positivity rate by immunoblot assay (RIBA). HCV-RNA positivity by both NC and NS primers was more frequent before IFN among responders. During IFN treatment, serum HCV-RNA was detectable, mostly at low titres, in 1 (NC positive) of the 11 responders and in 9 (4 NS positive and 5 NC positive) of the 11 non-responders. Among the four non-responders who were NS positive during IFN, three were NC positive before IFN. Serum HCV-RNA was always found in our post-transfusion or sporadic anti-HCV positive patients with CH. Viraemia generally decreased during IFN treatment, but no available HCV markers clearly distinguished responders from non-responders before IFN treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283753     DOI: 10.1002/jmv.1890380309

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

Authors:  E Villa; P Trande; A Grottola; P Buttafoco; A M Rebecchi; T Stroffolini; F Callea; A Merighi; L Camellini; P Zoboli; R Cosenza; L Miglioli; P Loria; R Iori; N Carulli; F Manenti
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

2.  Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up.

Authors:  G Diodati; P Bonetti; A Tagger; C Casarin; F Noventa; M Ribero; M Fasola; A Ruol; G Realdi
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

Review 3.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

4.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR.

Authors:  N C Besnard; P M Andre
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

6.  Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy.

Authors:  R Fukuda; N Ishimura; S Ishihara; A Tokuda; S Satoh; S Sakai; S Akagi; M Watanabe; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

7.  IgM and IgG antibodies to hepatitis C virus in patients with mixed cryoglobulinaemia.

Authors:  A L'Abbate; S Cutrupi; M Rognetta; C Fabiano; A Craxi
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 8.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 9.  Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

Authors:  B J Veldt; G Saracco; N Boyer; C Cammà; A Bellobuono; U Hopf; I Castillo; O Weiland; F Nevens; B E Hansen; S W Schalm
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

10.  Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.

Authors:  A J Czaja; S Magrin; C Fabiano; G Fiorentino; O Diquattro; A Craxi; L Pagliaro
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.